BONE BIOLOGICS CORP

BBLGNASDAQ

🏆 #5393 by market capEarnings Nov 12US Equity

$582.24▲ $3.14 (+0.54%)

Simulated price

🔔

Track BBLG

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 0.5%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$1M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Good

No chart data available for BBLG.

Trading Snapshot

Day Range: $579.95 – $591.88
52-Week Range: $0.43 – $2.89
Volume: $2.65B
Avg Volume: $2.93B
Shares Outstanding: 1.8M
Next Earnings: Nov 8, 2026

Fundamentals Snapshot

Annual Revenue: $162,837
Last Q Revenue: $44,867
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.61
Dividend Yield: —

Why Investors Own BBLG

✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
✓Healthy economics — 61% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BONE BIOLOGICS CORP

BBLG

Financial Trends

Revenue (TTM)

$162,837▲ +36.2% YoY

Gross Margin (TTM)

61.4%▲ +3.7% YoY

Operating Income (TTM)

$28,008▲ +36.2% YoY

Free Cash Flow (TTM)

$37,615▲ +36.2% YoY

StockOtter · stockotter.space

About BONE BIOLOGICS CORP

Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.

🦦